Zeitschrift für Gastroenterologie, Inhaltsverzeichnis Z Gastroenterol 2001; 39(1): 47-49DOI: 10.1055/s-2001-10699 Leitlinien der DGVS © Karl Demeter Verlag im Georg Thieme Verlag Stuttgart · New York Remission W. Kruis Köln Artikel empfehlen Abstract Artikel einzeln kaufen Volltext Referenzen Literatur 1 Courtney M G, Nunes D P, Bergin C F. et al . Colonoscopic but not histological appearances determine liklyhood of relapse of ulcerative colitis. Am J Gastroenterol. 1991; 86 243 (III) 2 Goodman M W, Eberle D E, Kuchler L A, Fossum E A. Microscopic activity predicts relapse in patients with distal ulcerative colitis on 4-aminosalicylate enemas. Gastroenterology. 1988; 96 A151 (III) 3 Riley S A, Mani V, Goodman M J, Dutt S, Herd M E. Microscopic activity in ulcerative colitis: What does it mean?. Gut. 1991; 32 174-178 (II b) 4 Ardizzone S, Petrillo M, Imbesi V. et al . Is maintenance therapy always necessary for patients with ulcerative colitis in remission?. Aliment Pharmacol Ther. 1999; 13 373-379 (I b) 5 Kornbluth A A, Salomon P, Sacks H S, Mitty R, Janowitz H D. Meta-analysis of the effectiveness of current drug therapy of ulcerative colitis. J Clin Gastroenterol. 1993; 16 215-218 (I a) 6 Sutherland L R, Roth D E, Beck P L. Alternatives to sulfasalazine: A meta-analysis of 5-ASA in the treatment of ulcerative colitis. Inflamm Bowel Dis. 1997; 3 65-78 (I a) 7 Sutherland L R, May G R, Shaffer E A. Sulfasalazine revisited: A meta-analysis of 5-ASA in the treatment of ulcerative colitis. Ann Intern Med. 1993; 118 540-549 (I a) 8 Marshall J K, Irvine E J. Rectal aminosalicylate therapy for distal ulcerative colitis: A meta-analysis. Aliment Pharmacol Ther. 1995; 9 293-300 (I a) 9 D’Albasio G, Pacini F, Camarri E. et al . Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: A randomized double-blind study. Am J Gastroenterol. 1997; 92 1143-1147 (I a) 10 Riley S A. What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?. Gut. 1998; 42 761-763 11 Azad Khan A K, Howes D T, Piris J, Truelove S C. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut. 1980; 21 232-240 (I b) 12 Fockens P, Mulder C JJ, Tytgat G NJ, Blok P, Ferwerda J. and the Dutch Pentasa Study Group . Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow- release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Eur J Gastroenterol Hepatol. 1995; 7 1025-1030 (I b) 13 Kiilerich S, Ladefoged K, Rannem T, Ranlov P J. and the Dutch olsalazine study group . Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. Gut. 1992; 33 252-255 (I b) 14 Biddle W L, Greenberger N J, Swan J T, McPhee M S, Miner P B. 5-Aminosalicylic acid enemas: Effective agent in maintaining remission in left-sided ulcerative colitis. Gastroenterology. 1988; 94 1075-1079 (I b) 15 Mantzaris G J, Hatzis A, Petraki K, Spilladi C, Triantaphyllou G. Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis. Dis Colon Rectum. 1994; 37 58-62 (I b) 16 D’Albasio G, Trallori G, Ghetti A. et al . Intermittent therapy with high dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis. Dis Colon Rectum. 1990; 33 394-397 (I b) 17 D’Albasio G, Paoluzi P, Campieri M. et al, and the Italian IBD study group . Maintenance treatment of ulcerative proctitis with mesalazine suppositories: A double-blind placebo-controlled trial. Am J Gastroenterol. 1998; 93 799-803 (I b) 18 Marteau P, Crand J, Foucault M, Ramboud J C. Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: A randomised double blind placebo controlled multicentre study. Gut. 1998; 42 195-199 (I b) 19 Sandborn W J. Azathioprine: State of the art in inflammatory bowel disease. Scand J Gastroenterol. 1998; 33 92-99 (Suppl. 225) 20 Kruis W, Schütz E, Fric P. et al . Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 1997; 11 853-858 (I b) 21 Rembacken B J, Snelling A M, Hawkey P M, Chalmers D M, Axon A TR. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial. Lancet. 1999; 354 635-639 (I b) 22 Fernández-Banares F, Hinojosa J, Sánchez-Lombrana J L. et al and the Spanish group for the study of Crohn’s disease and ulcerative colitis (GETECCU) . Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission of ulcerative colitis. Am J Gastroenterol. 1999; 94 427-433 (I b) 23 Pinczowski D, Ekbom A, Baron J, Yuen J, Adami H -O. Risk factors for colorectal cancer in patients with ulcerative colitis: A case control study. Gastroenterology. 1994; 107 117-120 (III) 24 Moody G A, Jayanthi V, Probert C SJ, Mac Kay H, Mayberry J F. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: A retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol. 1996; 8 1179-1183 (III)
